Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Applications of Delgocitinib Cream 1, 3, 8, 20 mg/g for 8 Weeks in Adult Subjects With Mild to Severe Atopic Dermatitis.

NCT03725722 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT03725722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03725722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Applications of Delgocitinib Cream 1, 3, 8, 20 mg/g for 8 Weeks in Adult Subjects With Mild to Severe Atopic Dermatitis.
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2018
Completion date
May 19, 2020
Enrollment
251 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis